Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 As a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Conditions
Interventions
JSP191
Locations
2
United States
Memorial Healthcare System
Hollywood, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Start Date
June 19, 2023
Primary Completion Date
October 21, 2024
Completion Date
October 21, 2024
Last Updated
February 27, 2025
Lead Sponsor
Jasper Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions